This is the first episode of a new monthly series of the neurotech industry round-up. If you don't have time to scan the headlines every day, listen to this podcast to get a summary of the news over that last month. Joining Ladan is Jen French and Jim Cavuoto from Neurotech Reports to review what is drawing attention in the neurotechnology industry. Some of the headlines focused on regulatory approvals of devices in the areas of heart failure, sleep apnea, migraine, and Parkinson's disease, as well as the passing of the reign of NeuroPace from Frank Fischer to Michael Favet. We also highlighted the market of obesity and the variety of neurotechnology approaches for the treatment of this condition.

3 Takeaways:

1. Several neurotech devices gain regulatory approval of the last month as the neurotech competition heats up.
2. The research and commercialization of devices for the treatment of obesity explands with an array of approaches.
3. Recent development from the company Humm who is marketing a non-invasive tACS device and research from the University of Houston in the area of PTSD.